The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: A meta-analysis

Arnold Nagy, Péter Mátrai, P. Hegyi, Hussain Alizadeh, Judit Bajor, L. Czopf, Zoltán Gyöngyi, Zoltán Kiss, Katalin Márta, M. Simón, Ágnes Lilla Szilágyi, Gábor Veres, Bernadett Mosdósi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background: Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The diagnosis is based on the underlying symptoms of arthritis with an exclusion of other diseases Biologic agents are increasingly used on the side of disease-modifying anti-rheumatic drugs (DMARD) in JIA treatment. Main body: The aim of this meta-analysis was to investigate the observed infections in JIA children during tumor necrosis factor (TNF)-alpha inhibitor therapy. A systematic search of three databases (Medline via PubMed, Embase, Cochrane Library) was carried out up to May 2018. Published trials that evaluated the infectious adverse events in patients receiving TNF-alpha inhibitor vs. a control group were included in the analysis. Full-text data extraction was carried out independently by the investigators from ten relevant publications. 1434 patients received TNF-alpha inhibitor therapy; the control group consisted of 696 subjects. The analysis presented the risk of infection in the active treatment group (OR = 1.13; 95% CI: 0.76-1.69; p = 0.543). The majority of infections were upper respiratory tract infections (URTIs). Furthermore, the subgroup analysis demonstrated a higher infection rate in the observed localization. Conclusion: Anti-TNF therapy slightly but not significantly increases the incidence of infection in JIA children compared to other therapies (GRADE: moderate evidence). The most common infections reported were mild URTIs. Further studies with larger patients number with a strong evidence level are crucially needed to finalize the answer whether anti-TNF therapy elevates and if yes on what extent the incidence of infection in JIA children. Trial registration: Prospero: CRD42017067873.

Original languageEnglish
Article number4
JournalPediatric Rheumatology
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 18 2019

Fingerprint

Juvenile Arthritis
Meta-Analysis
Tumor Necrosis Factor-alpha
Incidence
Infection
Respiratory Tract Infections
Therapeutics
Control Groups
Antirheumatic Agents
Biological Factors
Rheumatic Diseases
PubMed
Libraries
Arthritis
Publications
Chronic Disease
Research Personnel
Databases

Keywords

  • DMARD
  • Infection
  • JIA
  • Placebo
  • TNF-alpha inhibitor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Rheumatology
  • Immunology and Allergy

Cite this

The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children : A meta-analysis. / Nagy, Arnold; Mátrai, Péter; Hegyi, P.; Alizadeh, Hussain; Bajor, Judit; Czopf, L.; Gyöngyi, Zoltán; Kiss, Zoltán; Márta, Katalin; Simón, M.; Szilágyi, Ágnes Lilla; Veres, Gábor; Mosdósi, Bernadett.

In: Pediatric Rheumatology, Vol. 17, No. 1, 4, 18.01.2019.

Research output: Contribution to journalReview article

Nagy, A, Mátrai, P, Hegyi, P, Alizadeh, H, Bajor, J, Czopf, L, Gyöngyi, Z, Kiss, Z, Márta, K, Simón, M, Szilágyi, ÁL, Veres, G & Mosdósi, B 2019, 'The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: A meta-analysis', Pediatric Rheumatology, vol. 17, no. 1, 4. https://doi.org/10.1186/s12969-019-0305-x
Nagy, Arnold ; Mátrai, Péter ; Hegyi, P. ; Alizadeh, Hussain ; Bajor, Judit ; Czopf, L. ; Gyöngyi, Zoltán ; Kiss, Zoltán ; Márta, Katalin ; Simón, M. ; Szilágyi, Ágnes Lilla ; Veres, Gábor ; Mosdósi, Bernadett. / The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children : A meta-analysis. In: Pediatric Rheumatology. 2019 ; Vol. 17, No. 1.
@article{3da0b6c19e7d4fdf9dc30105187a0563,
title = "The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: A meta-analysis",
abstract = "Background: Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The diagnosis is based on the underlying symptoms of arthritis with an exclusion of other diseases Biologic agents are increasingly used on the side of disease-modifying anti-rheumatic drugs (DMARD) in JIA treatment. Main body: The aim of this meta-analysis was to investigate the observed infections in JIA children during tumor necrosis factor (TNF)-alpha inhibitor therapy. A systematic search of three databases (Medline via PubMed, Embase, Cochrane Library) was carried out up to May 2018. Published trials that evaluated the infectious adverse events in patients receiving TNF-alpha inhibitor vs. a control group were included in the analysis. Full-text data extraction was carried out independently by the investigators from ten relevant publications. 1434 patients received TNF-alpha inhibitor therapy; the control group consisted of 696 subjects. The analysis presented the risk of infection in the active treatment group (OR = 1.13; 95{\%} CI: 0.76-1.69; p = 0.543). The majority of infections were upper respiratory tract infections (URTIs). Furthermore, the subgroup analysis demonstrated a higher infection rate in the observed localization. Conclusion: Anti-TNF therapy slightly but not significantly increases the incidence of infection in JIA children compared to other therapies (GRADE: moderate evidence). The most common infections reported were mild URTIs. Further studies with larger patients number with a strong evidence level are crucially needed to finalize the answer whether anti-TNF therapy elevates and if yes on what extent the incidence of infection in JIA children. Trial registration: Prospero: CRD42017067873.",
keywords = "DMARD, Infection, JIA, Placebo, TNF-alpha inhibitor",
author = "Arnold Nagy and P{\'e}ter M{\'a}trai and P. Hegyi and Hussain Alizadeh and Judit Bajor and L. Czopf and Zolt{\'a}n Gy{\"o}ngyi and Zolt{\'a}n Kiss and Katalin M{\'a}rta and M. Sim{\'o}n and Szil{\'a}gyi, {{\'A}gnes Lilla} and G{\'a}bor Veres and Bernadett Mosd{\'o}si",
year = "2019",
month = "1",
day = "18",
doi = "10.1186/s12969-019-0305-x",
language = "English",
volume = "17",
journal = "Pediatric Rheumatology",
issn = "1546-0096",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children

T2 - A meta-analysis

AU - Nagy, Arnold

AU - Mátrai, Péter

AU - Hegyi, P.

AU - Alizadeh, Hussain

AU - Bajor, Judit

AU - Czopf, L.

AU - Gyöngyi, Zoltán

AU - Kiss, Zoltán

AU - Márta, Katalin

AU - Simón, M.

AU - Szilágyi, Ágnes Lilla

AU - Veres, Gábor

AU - Mosdósi, Bernadett

PY - 2019/1/18

Y1 - 2019/1/18

N2 - Background: Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The diagnosis is based on the underlying symptoms of arthritis with an exclusion of other diseases Biologic agents are increasingly used on the side of disease-modifying anti-rheumatic drugs (DMARD) in JIA treatment. Main body: The aim of this meta-analysis was to investigate the observed infections in JIA children during tumor necrosis factor (TNF)-alpha inhibitor therapy. A systematic search of three databases (Medline via PubMed, Embase, Cochrane Library) was carried out up to May 2018. Published trials that evaluated the infectious adverse events in patients receiving TNF-alpha inhibitor vs. a control group were included in the analysis. Full-text data extraction was carried out independently by the investigators from ten relevant publications. 1434 patients received TNF-alpha inhibitor therapy; the control group consisted of 696 subjects. The analysis presented the risk of infection in the active treatment group (OR = 1.13; 95% CI: 0.76-1.69; p = 0.543). The majority of infections were upper respiratory tract infections (URTIs). Furthermore, the subgroup analysis demonstrated a higher infection rate in the observed localization. Conclusion: Anti-TNF therapy slightly but not significantly increases the incidence of infection in JIA children compared to other therapies (GRADE: moderate evidence). The most common infections reported were mild URTIs. Further studies with larger patients number with a strong evidence level are crucially needed to finalize the answer whether anti-TNF therapy elevates and if yes on what extent the incidence of infection in JIA children. Trial registration: Prospero: CRD42017067873.

AB - Background: Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The diagnosis is based on the underlying symptoms of arthritis with an exclusion of other diseases Biologic agents are increasingly used on the side of disease-modifying anti-rheumatic drugs (DMARD) in JIA treatment. Main body: The aim of this meta-analysis was to investigate the observed infections in JIA children during tumor necrosis factor (TNF)-alpha inhibitor therapy. A systematic search of three databases (Medline via PubMed, Embase, Cochrane Library) was carried out up to May 2018. Published trials that evaluated the infectious adverse events in patients receiving TNF-alpha inhibitor vs. a control group were included in the analysis. Full-text data extraction was carried out independently by the investigators from ten relevant publications. 1434 patients received TNF-alpha inhibitor therapy; the control group consisted of 696 subjects. The analysis presented the risk of infection in the active treatment group (OR = 1.13; 95% CI: 0.76-1.69; p = 0.543). The majority of infections were upper respiratory tract infections (URTIs). Furthermore, the subgroup analysis demonstrated a higher infection rate in the observed localization. Conclusion: Anti-TNF therapy slightly but not significantly increases the incidence of infection in JIA children compared to other therapies (GRADE: moderate evidence). The most common infections reported were mild URTIs. Further studies with larger patients number with a strong evidence level are crucially needed to finalize the answer whether anti-TNF therapy elevates and if yes on what extent the incidence of infection in JIA children. Trial registration: Prospero: CRD42017067873.

KW - DMARD

KW - Infection

KW - JIA

KW - Placebo

KW - TNF-alpha inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85060128903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060128903&partnerID=8YFLogxK

U2 - 10.1186/s12969-019-0305-x

DO - 10.1186/s12969-019-0305-x

M3 - Review article

C2 - 30658717

AN - SCOPUS:85060128903

VL - 17

JO - Pediatric Rheumatology

JF - Pediatric Rheumatology

SN - 1546-0096

IS - 1

M1 - 4

ER -